Could an immune booster improve rectal cancer treatment?
NCT ID NCT03516708
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This study is testing whether adding a drug called epacadostat to standard radiation and chemotherapy can help shrink advanced rectal tumors before surgery. About 49 adults with locally advanced rectal cancer will receive the combination. The goal is to find the best dose and see if it improves outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Henry Ford Cancer Institute
WITHDRAWNDetroit, Michigan, 48202, United States
-
University of California Irvine - Chao Family Comprehensive Cancer Center
WITHDRAWNOrange, California, 92868, United States
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Contact
Contact
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Epacadostat (a drug that may help the immune system fight cancer)
What this could lead to
If successful, this could lead to a more effective treatment for locally advanced rectal cancer, potentially improving tumor shrinkage before surgery and long-term outcomes.
What could go wrong
This is an early-phase trial (Phase I/II) with a small number of participants (49). The drug may not improve outcomes or could cause additional side effects. Results may not apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.